Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes
Author:
Affiliation:
1. Worldwide Research and Development, Pfizer Inc; Cambridge MA USA
2. Aggarwal & Associates Ltd; Brampton Ontario Canada
3. Department of Medicine; University of Debrecen Medical and Health Science Centre; Nagyerdei krt Hungary
Funder
Pfizer
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12474/fullpdf
Reference13 articles.
1. Standards of medical care in diabetes - 2013;American Diabetes Association;Diabetes Care,2013
2. The prevalence of meeting HbA1c, blood pressure, and LDL goals among people with diabetes, 1988-2010;Casagrande;Diabetes Care,2013
3. GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?;Matschinsky;Trends Pharmacol Sci,2013
Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Unveiling the Influence of a High-Fat Meal on the Pharmacokinetics of Oral Globalagliatin, A Glucokinase Activator, in Healthy Chinese Volunteers;Drugs in R&D;2023-11-20
2. Population Pharmacokinetic/Pharmacodynamic Analysis of the Glucokinase Activator PB201 in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus: Facilitating the Clinical Development of PB201 in China;Clinical Pharmacokinetics;2023-11-20
3. Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB‐201;CPT: Pharmacometrics & Systems Pharmacology;2023-04-20
4. Design, synthesis, in silico, and in vitro evaluation of benzylbenzimidazolone derivatives as potential drugs on α-glucosidase and glucokinase as pharmacological targets;RSC Advances;2023
5. A multicentre, randomized, double‐blind, parallel, active‐ and placebo‐controlled Phase 3 clinical study of the glucokinase activator PB ‐201 in treatment‐naive patients with type 2 diabetes mellitus: A study protocol;Diabetes, Obesity and Metabolism;2022-11-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3